ERBB2 and breast cancer: Trastuzumab (Herceptin), a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) is used for the treatment of breast cancer subtypes overexpressing HER2 and has revolutionized outcomes of patients with HER2-positive breast cancer.